Anavex Stock: The Pediatric Rett Trial Failure Is Disastrous (NASDAQ:AVXL)

[ad_1]

Arrows are not targeted, Failure to attack the target. unsuccessful.

StudioEasy

In my October article, I discussed the statistical basis for saying that the Anavex Life Sciences (AVXL) Alzheimer’s trial was a failure. This trial of blarcamesine, the company said, demonstrated slowing of cognitive decline in a key phase 2b/3

[ad_2]
Source link

Leave a Reply

Your email address will not be published. Required fields are marked *